Supplementary Table 5. Shifts in CKD stage (OL SAS)

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **TAF-TAF****(*n* = 212)** | **TDF-TAF****(*n* = 99)** | ***p*** |
| CKD stage\* at baseline, *n* (%) | NA |
| Stage 1 | 179 (84.4) | 85 (85.9) |
| Stage 2 | 32 (15.1) | 12 (12.1) |
| Stage 3 | 1 (0.5) | 2 (2.0) |
| Stage 4 | 0 | 0 |
| Shifts in CKD stage: baseline → week 144, *n* (%) | 0.0522 |
| Improved | 9 (4.2) | 1 (1.0) |
| Remained the same | 191 (90.1) | 88 (88.9) |
| Worsen | 12 (5.7) | 10 (10.1) |
| Shifts in CKD stage: baseline → week 240, *n*† (%) | 0.1731 |
| Improved | 6 (2.9) | 1 (1.0) |
| Remained the same | 181 (89.6) | 86 (88.7) |
| Worsen | 15 (7.4) | 10 (10.3) |

\*Defined by eGFR, Stage 1: ≥ 90 mL/m; Stage 2: ≥ 60 to < 90 mL/m; Stage 3: ≥ 30 to < 60 mL/m; Stage 4: < 30 mL/m; †Ten patients in the TAF-TAF group and two patients in the TDF-TAF group had missing data at week 240. CKD, chronic kidney disease; OL SAS, open-label safety analysis set; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.